Comparative review of imipenem/cilastatin versus meropenem.
Med Mal Infect
; 50(4): 316-322, 2020 Jun.
Article
en En
| MEDLINE
| ID: mdl-32035719
ABSTRACT
INTRODUCTION:
Carbapenems are broad-spectrum antibacterial molecules. Imipenem-cilastatin and meropenem are the two main molecules used in French healthcare services.OBJECTIVE:
We aimed to evaluate the relative strengths and weaknesses of these two molecules by considering their pharmacokinetic, pharmacodynamic, microbiological, and clinical properties. We demonstrated that imipenem-cilastatin and meropenem are not alike.METHOD:
Review of the literature by querying the MEDLINE network.RESULTS:
Imipenem-cilastatin is the first marketed molecule of the carbapenem class. It is more effective against Gram-positive cocci. Its stability does not allow for long infusions and its main adverse effect on the central nervous system limits its use. Meropenem is more effective against Gram-negative bacilli. Its stability and its milder adverse effects distinguish it from imipenem-cilastatin.CONCLUSION:
Meropenem is preferred for daily use in healthcare services when carbapenems are to be used.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Combinación Cilastatina e Imipenem
/
Meropenem
/
Antibacterianos
Límite:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Pregnancy
Idioma:
En
Revista:
Med Mal Infect
Año:
2020
Tipo del documento:
Article